Robert Newton

Robert Newton

Auto-generated profile, based on publicly available information

Robert Newton

Affiliation Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2000 in Thorax
Verified
Journal Article
Open access
PDF file
RNRobert Newton
Robert Newton
Therapeutically, the ability to suppress a number of inflammatory indices makes glucocorticoids among the most potent anti-inflammatory agents currently available for the treatment of chronic inflammatory diseases such as asthma.2 , 3 The clinical efficacy of synthetic glucocorticoids such as prednisolone or dexamethasone stems from their ability to mimic natural glucocorticosteroids. Bodily insults, including inflammation, pain, infection or even mental stress, lead to activation of the hypothalamic-pituitary-adrenal (HPA) axis. These stimuli cause excitation of the hypothalamus, which responds by releasing corticotropin releasing hormone (CRH) (also known as corticotropin releasing factor, CRF). CRH then acts on the anterior pituitary to induce synthesis and release of adrenocorticotropic hormone (ACTH). ACTH in turn stimulates the adrenal cortex to release glucocorticoids such as cortisol. Once within the blood, cortisol is transported to target organs where it elicits numerous metabolic effects including increased blood glucose levels, stimulation of gluconeogenesis in the liver, and the mobilisation of both amino and fatty acids (fig 1). However, in addition to these metabolic effects, glucocorticoids are also potent endogenous immunological suppressors. Thus, whilst the anti-inflammatory power of synthetic glucocorticoids derives from endogenous anti-inflammatory mechanisms, the clinical usefulness of these drugs is limited by HPA insufficiency and effects on bone metabolism in addition to the metabolic effects listed above. In this respect, it is often stated that the metabolic effects of glucocorticoids result from increased transcription of genes such as tyrosine aminotransferase (TAT) and phoshoenolpyruvate carboxykinase (PEPCK),10-13whereas the anti-inflammatory properties are attributed to negative transcriptional effects on inflammatory gene expression.12-14 However, this may not wholly be the case.

1 August 1997 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
RNRobert Newton
Robert Newton
LKLieske M.E. Kuitert
Lieske M.E. Kuitert
MBMartin Bergmann
Martin Bergmann
IAIan Adcock
Ian Adcock
PBPeter Barnes
Peter Barnes

1 October 2004 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
PDF file
LDLouise E. Donnelly
Louise E. Donnelly
RNRobert Newton
Robert Newton
GKGina E. Kennedy
Gina E. Kennedy
PFPeter S. Fenwick
Peter S. Fenwick
RLRachel H. F. Leung
Rachel H. F. Leung
PBPeter Barnes
Peter Barnes
Resveratrol (3,4′,5-trihydroxystilbene) is a polyphenolic stilbene found in the skins of red fruits, including grapes, that may be responsible for some of the health benefits ascribed to consumption of red wine. Resveratrol has been shown to have antioxidant properties and can act as an estrogen agonist. This study examined the anti-inflammatory effects of resveratrol on human airway epithelial cells. Resveratrol and the related molecule quercetin, but not deoxyrhapontin, inhibited IL-8 and granulocyte-macrophage colony-stimulating factor release from A549 cells. Neither the estrogen receptor antagonist tamoxifen nor the glucocorticoid antagonist mifepristone altered the inhibitory effect of resveratrol. The mechanism of resveratrol action was investigated further using luciferase reporter genes stably transfected into A549 cells. Resveratrol and quercetin inhibited NF-κB-, activator protein-1-, and cAMP response element binding protein-dependent transcription to a greater extent than the glucocorticosteroid dexamethasone. These compounds also had no significant effect on acetylation or deacetylation of core histones. Resveratrol, but not estradiol or N-acetyl cysteine, inhibited cytokine-stimulated inducible nitric oxide synthase expression and nitrite production (IC50 = 3.6 ± 2.9 μM) in human primary airway epithelial cells. Resveratrol also inhibited granulocyte-macrophage colony-stimulating factor release (IC50 = 0.44 ± 0.17 μM), IL-8 release (IC50 = 4.7 ± 3.3 μM), and cyclooxygenase-2 expression in these cells. This study demonstrates that resveratrol and quercetin have novel nonsteroidal anti-inflammatory activity that may have applications for the treatment of inflammatory diseases.

1 October 2007 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
RNRobert Newton
Robert Newton
NHNeil S. Holden
Neil S. Holden
Glucocorticoids (corticosteroids) are highly effective in combating inflammation in the context of a variety of diseases. However, clinical utility can be compromised by the development of side effects, many of which are attributed to the ability of the glucocorticoid receptor (GR) to induce the transcription of, or transactivate, certain genes. By contrast, the anti-inflammatory effects of glucocorticoids are due largely to their ability to reduce the expression of pro-inflammatory genes. This effect has been predominantly attributed to the repression of key inflammatory transcription factors, including AP-1 and NF-κB, and is termed transrepression. The ability to functionally separate these transcriptional functions of GR has prompted a search for dissociated GR ligands that can differentially induce transrepression but not transactivation. In this review, we present evidence that post-transcriptional mechanisms of action are highly important to the anti-inflammatory actions of glucocorticoids. Furthermore, we present the case that mechanistically distinct forms of glucocorticoid-inducible gene expression are critical to the development of anti-inflammatory effects by repressing inflammatory signaling pathways and inflammatory gene expression at multiple levels. Considerable care is therefore required to avoid loss of anti-inflammatory effectiveness in the development of novel transactivation-defective ligands of GR.

1 June 2001 in Molecular Human Reproduction
Verified
Journal Article
Open access
PDF file
VAV.C. Allport
V.C. Allport
DPD. Pieber
D. Pieber
DSD.M. Slater
D.M. Slater
RNR. Newton
R. Newton
JWJ.O. White
J.O. White
PBP.R. Bennett
P.R. Bennett
Human labour is associated with the up-regulation of prostaglandins within the uterus, synthesized via the type-2 cyclo-oxygenase enzyme (COX-2). These lead to remodelling of the fetal membranes and cervix and to stimulation of myometrial contractions. In the human, the principal source of prostaglandins is the amnion. Progesterone acts to promote myometrial quiescence, and in many species the onset of labour is preceded by withdrawal of progesterone. Humans show no systemic progesterone withdrawal, although biochemical changes within the uterus are similar to those in other species. A mutual negative interaction between the transcription factor nuclear factor (NF)-κB and the progesterone receptor (PR) has been reported. Using transient transfections and assays for transcriptional activation and promoter binding, we have shown that there is constitutive activity of NF-κB in amnion cells at the time of labour, and that COX-2 expression depends upon NF-κB. In cells obtained before labour, in which NF-κB activity is low, increasing the concentration of PR represses NF-κB dependent transcription, while stimulation with IL-1β both increases NF-κB activity and represses PR activity. Our data suggest that human labour is associated with constitutive NF-κB activity within the amnion, which functions to increase the expression of COX-2 and appears to contribute to the ‘functional progesterone withdrawal’.

1 August 1996 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
MGMark A. Giembycz
Mark A. Giembycz
CCChristopher J. Corrigan
Christopher J. Corrigan
JSJoachim Seybold
Joachim Seybold
RNRobert Newton
Robert Newton
PBPeter Barnes
Peter Barnes
The cyclic AMP phosphodiesterases (PDE) expressed by CD4+and CD8+T‐lymphocytes purified from the peripheral blood of normal adult subjects were identified and characterized, and their role in modulating proliferation and the biosynthesis of interleukin (IL)‐2 and interferon (IFN)‐γ evaluated. In lysates prepared from both subsets, SK&F 95654 (PDE3 inhibitor) and rolipram (PDE4 inhibitor) suppressed cyclic AMP hydrolysis indicating the presence of PDE3 and PDE4 isoenzymes in these cells. Differential centrifugation and subsequent inhibitor and kinetic studies revealed that the particulate fraction contained, predominantly, a PDE3 isoenzyme. In contrast, the soluble fraction contained a PDE4 (∼65% of total activity) and, in addition, a novel enzyme that had the kinetic characteristics of the recently identified PDE7. Reverse transcription‐polymerase chain reaction (RT‐PCR) studies with primer pairs designed to recognise unique sequences in the human PDE4 and PDE7 genes amplified cDNA fragments that corresponded to the predicted sizes of HSPDE4A, HSPDE4B, HSPDE54D and HSPDE7. No message was detected for HSPDE4C after 35 cycles of amplification. Functionally, rolipram inhibited phytohaemagglutinin‐ (PHA) and anti‐CD3‐induced proliferation of CD4+and CD8+T‐lymphocytes, and the elaboration of IL‐2, which was associated with a three to four fold increase in cyclic AMP mass. In all experiments, however, rolipram was approximately 60 fold more potent at suppressing IL‐2 synthesis than at inhibiting mitogenesis. In contrast, SK&F 95654 failed to suppress proliferation and cytokine generation, and did not elevate the cyclic AMP content in T‐cells. Although inactive alone, SK&F 95654 potentiated the ability of rolipram to suppress PHA‐ and anti‐CD3‐induced T‐cell proliferation, and PHA‐induced IL‐2 release. When a combination of phorbol myristate acetate (PMA) and ionomycin were used as a co‐mitogen, rolipram did not affect proliferation but, paradoxically, suppressed IL‐2 release indicating that cyclic AMP can inhibit mitogenesis by acting at, or proximal to, the level of inositol phospholipid hydrolysis. Collectively, these data suggest that PDE3 and PDE4 isoenzymes regulate the cyclic AMP content, IL‐2 biosynthesis and proliferation in human CD4+and CD8+T‐lymphocytes. However, the ability of rolipram to suppress markedly mitogen‐induced IL‐2 generation without affecting T‐cell proliferation suggests that growth and division of T‐lymphocytes may be governed by mediators in addition to IL‐2. Finally, T‐cells have the potential to express PDE7, although elucidating the functional role of this enzyme must await the development of selective inhibitors.